Stock Track | Dianthus Therapeutics Soars 5.09% Intraday on Multiple Analyst Upgrades and Price Target Increases
Stock Track
Mar 11
Dianthus Therapeutics Inc. (DNTH) saw its stock price soar 5.09% during intraday trading on Tuesday, driven by positive analyst sentiment.
The surge follows a series of analyst upgrades and significant price target increases. Wedbush raised its price target on Dianthus to $80 from $55 while maintaining an Outperform rating. Raymond James upgraded the stock to Strong Buy from Outperform and more than doubled its price target to $123 from $63. Additionally, Baird raised its price target to $132 from $67, keeping an Outperform rating on the shares.
These coordinated analyst actions reflect growing confidence in the company's prospects and have contributed to increased investor buying activity during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.